The global demand for Allergy Immunotherapy Market is presumed to reach the valuation of nearly USD 7.08 MN by 2030 from USD 3.27 MN in 2022 with a CAGR of 13.97% under the study period of 2023-2030.
Allergy immunotherapy is a medical treatment used to reduce or stop allergy attacks caused by exposure to allergens like grass pollens, house dust mites, and bee venom. The typical treatment method involves regular allergy shots containing a tiny amount of the allergens triggering the allergic reactions to stimulate the immune system. Different types of immunotherapy exist based on the administration route. The effectiveness of this therapy depends on the length of the treatment program and the dose of the allergen.
Market Dynamics
Both children and adults can undergo allergy immunotherapy. While treating older adults using allergy immunotherapy, their pre-existing medical conditions are taken into consideration. The cost of the allergen immunotherapy varies by country and administration route. Rising pollution levels and the prevalence of chronic disorders due to allergic reactions will serve as the main impetus for this market's growth. The effectiveness of immunotherapy in treating different types of allergies like allergic rhinitis, allergic asthma, conjunctivitis (eye allergy), or stinging insect allergy compared to traditional methods will benefit this market's growth. Growing awareness and approval for an immunotherapy-based treatment for allergies in patients of all age groups will boost the market growth. Increased healthcare investments in the research and development of high-quality allergy shots to cover several types of known allergens will be a market booster. The major hurdle for the growth of this market is the lack of awareness about allergy immunotherapy.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of allergy immunotherapy.
Market Segmentation
This section of the allergy immunotherapy market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Treatment Type
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
By Allergy Type
- Allergic Rhinitis
- Allergic Asthma
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Allergy Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Allergy Immunotherapy Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the allergy immunotherapy market include Adamis Pharmaceuticals Corporation,ALK-Abelló A/S,Allergy Therapeutics,ASIT Biotech,Circassia,DVB Technologies SA,DESENTUM OY,HAL Allergy B.V.,HollisterStier Allergy,LETIPharma,Merck KGaA,Mylan N.V.,Stallergenes Greer plc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.